Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE)

Next Previous
Search
Trial Profile

BILAG Biologics Prospective Cohort: The Use of Novel Biological Therapies in the Treatment of Systemic Lupus Erythematosus (SLE)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azathioprine (Primary) ; Mycophenolate mofetil (Primary) ; Antirheumatics; Belimumab; Cyclophosphamide; Immunomodulators; Immunosuppressants; Rituximab
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Biomarker; Therapeutic Use

    • Most Recent Events

    • 15 Jun 2024 Results (n=782) assessing discordance in clinical response and patient-reported outcomes commencing rituximab and belimumab presented at the 25th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results of all-cause mortality rate (MR) and the incidence of cancer in SLE patients receiving biologic and standard of care therapies, presented at the 24th Annual Congress of the European League Against Rheumatism
    • 03 Jun 2023 Results assessing differential response of patients with moderate-severe SLE in the UK by ethnic background, presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top